福泰制药Vertex Pharmaceuticals（VRTX）2025年第二季度业绩报告「NASDAQ」（英文版）（12页）.pdf

1、Vertex Reports Second Quarter 2025 Financial ResultsAugust 4,2025 Total revenue of$2.96 billion,a 12%increase compared to Q2 2024;reiterated full year 2025 financial guidance,including revenue guidance of$11.85 to$12 billion Continued strong execution of CASGEVY,ALYFTREK and JOURNAVX launches Rapid

2、advancement of next wave of clinical programs through pivotal development,with suzetrigine in DPN,zimislecel in T1D,povetacicept in IgANand pMN,and inaxaplin in AMKD David Altshuler,M.D.,PhD.,Chief Scientific Officer(CSO),announces intent to retire August 1,2026;as part of planned transition,Mark Bu

3、nnage,D.Phil.,SVP of Global Research,to assume role of CSO effective February 1,2026 BOSTON-(BUSINESS WIRE)-Aug.4,2025-Vertex Pharmaceuticals Incorporated(Nasdaq:VRTX)today reported consolidated financial results forthe second quarter ended June 30,2025,and reiterated full year 2025 financial guidan

4、ce.“Vertex delivered a strong quarter of revenue growth with each of our three product launches ALYFTREK,JOURNAVX,and CASGEVY contributing,as well as continued advancement of our clinical programs,”said Reshma Kewalramani,M.D.,Chief Executive Officer and President ofVertex.“As we enter the second ha

5、lf of the year,we are focused on expanding leadership in cystic fibrosis,executing the launches,advancing thepipeline,and preparing for submissions and commercialization in additional disease areas.”Dr.Kewalramani added,“I would like to express my deepgratitude to David for his exceptional scientifi

6、c vision and patient impact over the last 13 years.As CSO,David has been at the helm through thediscovery,development and approval of four CF medicines,our groundbreaking CRISPR/Cas9 gene-edited therapy,and our novel non-opioid painmedicine.As part of the planned transition,I am delighted that Mark